Are antimicrobial-impregnated catheters effective? Don't throw out the baby with the bathwater

Clinical Infectious Diseases

Volumn 38, Issue 9, 2004, Pages 1287-1292

  Crnich, Christopher J ^a   Maki, Dennis G ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CHLORHEXIDINE; MINOCYCLINE; RIFAMPICIN; SULFADIAZINE SILVER;

BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATE; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ECONOMIC EVALUATION; HUMAN; PRIORITY JOURNAL; REVIEW; ARTICLE; CENTRAL VENOUS CATHETERIZATION; COST BENEFIT ANALYSIS; ECONOMICS; INDWELLING CATHETER; INFANT; SEPSIS;

ANTI-INFECTIVE AGENTS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; COST-BENEFIT ANALYSIS; HUMANS; INFANT; SEPSIS;

EID: 2342639544     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383470     Document Type: Review

References (78)

1. Ramsay J, Nolte F, Schwarzmann S. Incidence of catheter colonization and catheter-related infection with an antiseptic impregnated triple lumen catheter [abstract]. Crit Care Med 1994; 22:A115
2. Bach A, Bohrer H, Bottiger B, Motsch J, Martin E. Reduction of bacterial colonization of triple-lumen catheters with antiseptic bonding in septic patients [abstract A261]. Anesthesiology 1994; 81.
3. Trazzera S, Stern G, Rakesh B, Sinna S, Reiser P. Examination of antimicrobial-coated central venous catheters in patients at high-risk for catheter related infections in a medical intensive care unit and leukemia/bone marrow transplant unit [abstract A152]. Crit Care Med 1995; 23.
4. Bach A, Schmidt H, Bottiger B, et al. Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters. J Antimicrob Chemother 1996; 37:315-22.
5. Ciresi DL, Albrecht RM, Volkers PA, Scholten DJ. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. Am Surg 1996; 62:641-6.
6. Pemberton LB, Ross V, Cuddy P, Kremer H, Fessler T, McGurk E. No difference in catheter sepsis between standard and antiseptic central venous catheters: a prospective randomized trial. Arch Surg 1996; 131:986-9.
7. van Heerden PV, Webb SA, Fong S, Golledge CL, Roberts BL, Thompson WR. Central venous catheters revisited - infection rates and an assessment of the new Fibrin Analysing System brush. Anaesth Intensive Care 1996; 24:330-3.
8. George SJ, Vuddamalay P, Boscoe MJ. Antiseptic-impregnated central venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients. Eur J Anaesthesiol 1997; 14:428-31.
9. Logghe C, Van Ossel C, D'Hoore W, Ezzedine H, Wauters G, Haxhe JJ. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. J Hosp Infect 1997; 37:145-56.
10. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann Intern Med 1997; 127:257-66.
11. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. Ann Intern Med 1997; 127:267-74.
12. Tennenberg S, Lieser M, McCurdy B, et al. A prospective randomized trial of an antibiotic-and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Arch Surg 1997; 132:1348-51.
13. Heard SO, Wagle M, Vijayakumar E, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med 1998; 158:81-7.
14. Collin GR. Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continuous quality improvement project. Chest 1999; 115:1632-40.
15. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med 1999; 340:1-8.
16. Hannan M, Juste RN, Umasanker S, et al. Antiseptic-bonded central venous catheters and bacterial colonisation. Anaesthesia 1999; 54:868-72.
17. Marik PE, Abraham G, Careau P, Varon J, Fromm RE Jr. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters. Crit Care Med 1999; 27:1128-31.
18. Sheng WH, Ko WJ, Wang JT, Chang SC, Hsueh PR, Luh KT. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in intensive care unit patients. Diagn Microbiol Infect Dis 2000; 38:1-5.
19. Rijnders BJ, Van Wijngaerden E, Peetermans WE. Catheter-tip colonization as a surrogate end point in clinical studies on catheter-related bloodstream infection: how strong is the evidence? Clin Infect Dis 2002; 35:1053-8.
20. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999; 281:261-7.
21. Marin MG, Lee JC, Skurnick JH. Prevention of nosocomial bloodstream infections: effectiveness of antimicrobial-impregnated and heparin-bonded central venous catheters. Crit Care Med 2000; 28:3332-8.
22. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices. Clin Infect Dis 2002; 34:1232-42.
23. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999; 282:554-60.
24. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters. Chest 2003; 124:275-84.
25. Saint S. Prevention of intravascular catheter-associated infections. In: Shojania KG, Duncan BW, McDonald KM, Wachter RM, eds. Making health care safer: a critical analysis of patient safety practices. Rockville, MD: Agency for Healthcare Research and Quality, 2001: 163-84.
26. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2002; 35:1281-307.
27. McConnell SA, Gubbins PO, Anaisse EJ. Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection? Clin Infect Dis 2003; 37:65-72.
28. Tavel JA, Miller KD, Masur H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infect Dis 1999; 28:643-76.
29. Siegman-Igra Y, Anglim AM, Shapiro DE, Adal KA, Strain BA, Farr BM. Diagnosis of vascular catheter-related bloodstream infection: a meta-analysis. J Clin Microbiol 1997; 35:928-36.
30. Crnich CJ, Maki DG. The role of intravascular devices in sepsis. Curr Infect Dis Rep 2001; 3:497-506.
31. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32:1249-72.
32. Bradford Hill A. The environment and disease: association or causation? Proc R Soc Med 1965; 58:295-300.
33. Martin MA, Pfaller MA, Wenzel RP. Coagulase-negative staphylococcal bacteremia: mortality and hospital stay. Ann Intern Med 1989; 110:9-16.
34. Thylefors JD, Harbarth S, Pittet D. Increasing bacteremia due to coagulase-negative staphylococci: fiction or reality? Infect Control Hosp Epidemiol 1998; 19:581-9.
35. Finkelstein R, Fusman R, Oren I, Kassis I, Hashman N. Clinical and epidemiologic significance of coagulase-negative staphylococci bacteremia in a tertiary care university Israeli hospital. Am J Infect Control 2002; 30:21-5.
36. Benjamin DK Jr, Ross K, McKinney RE Jr, Benjamin DK, Auten R, Fisher RG. When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics 2000; 106:712-8.
37. Isaacs D, Australasian Study Group For Neonatal Infections. A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal units. Arch Dis Child Fetal Neonatal Ed 2003; 88:F89-93.
38. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol 1999; 20:396-401.
39. Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999; 160:976-81.
40. Rello J, Ochagavia A, Sabanes E, et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med 2000; 162:1027-30.
41. Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990; 89:137-41.
42. Conterno LO, Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998; 19:32-7.
43. Jensen AG, Wachmann CH, Poulsen KB, et al. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med 1999; 159:1437-44.
44. Gopal AK, Fowler VG Jr, Shah M, et al. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol 2000; 18:1110-5.
45. Topeli A, Unal S, Akalin HE. Risk factors influencing clinical outcome in Staphylococcus aureus bacteraemia in a Turkish University Hospital. Int J Antimicrob Agents 2000; 14:57-63.
46. Gonzalez-Barca E, Carratala J, Mykietiuk A, Fernandez-Sevilla A, Gudiol F. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis 2001; 20:117-9.
47. Zeylemaker MM, Jaspers CA, van Kraaij MG, Visser MR, Hoepelman IM. Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2001; 20:380-4.
48. Torre-Cisneros J, Herrero C, Canas E, Reguera JM, De La Mata M, Gomez-Bravo MA. High mortality related with Staphylococcus aureus bacteremia after liver transplantation. Eur J Clin Microbiol Infect Dis 2002; 21:385-8.
49. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989; 149:2349-53.
50. Pittet D, Li N, Woolson R, Wenzel R. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997; 24:1068-78.
51. Valles J, Leon C, Alvarez-Lerma F. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Clin Infect Dis 1997; 24:387-95.
52. Launay O, Lortholary O, Bouges-Michel C, Jarrousse B, Bentata M, Guillevin L. Candidemia: a nosocomial complication in adults with late-stage AIDS. Clin Infect Dis 1998; 26:1134-41.
53. Lark RL, Chenoweth C, Saint S, Zemencuk JK, Lipsky BA, Plorde JJ. Four year prospective evaluation of nosocomial bacteremia: epidemiology, microbiology, and patient outcome. Diagn Microbiol Infect Dis 2000; 38:131-40.
54. Luzzati R, Amalfitano G, Lazzarini L, et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis 2000; 19:602-7.
55. Smith RL, Meixler SM, Simberkoff MS. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest 1991; 100:164-7.
56. Collignon PJ. Intravascular catheter associated sepsis: a common problem. Med J Aust 1994; 161:374-8.
57. Pittet D, Tarara D, Wenzel R. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598-601.
58. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 2001; 136:229-34.
59. Renaud B, Brun-Buisson C, Group IC-BS. Outcomes of primary and catheter-related bacteremia: a cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 2001; 163:1584-90.
60. Maki DG, Ringer M, Alvarado CJ. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991; 338:339-43.
61. Maki DG, Mermel LA, Kluger DM, et al. The efficacy of a chlorhexidine-impregnated sponge (Biopatch) for the prevention of intravascular catheter-related infection - a prospective, randomized, controlled, multicenter trial [abstract 1430]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2000:422.
62. Lidwell OM, Lowbury EJ, Whyte W, Blowers R, Stanley SJ, Lowe D. Effect of ultraclean air in operating rooms on deep sepsis in the joint after total hip or knee replacement: a randomized study. Br Med J (Clin Res Ed) 1982; 285:10-4.
63. Maki DG, Cobb L, Garman JK, Shapiro JM, Ringer M, Helgerson RB. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. Am J Med 1988; 85:307-14.
64. Humar A, Ostromecki A, Direnfield J, et al. Prospective randomized trial of 10% povidone-iodine versus 0.5% tincture of chlorhexidine as cutaneous antisepsis for prevention of central venous catheter infection. Clin Infect Dis 2000; 31:1001-7.
65. Garland JS, Alex CP, Mueller CD, et al. A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates. Pediatrics 2001; 107:1431-6.
66. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101-11.
67. Stein RS, Kayser J, Flexner JM. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer 1982; 50:2247-51.
68. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986; 80:13-20.
69. Hann IM, Prentice HG, Corringham R, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982; 1:826-9.
70. Wingard JR, Vaughan WP, Braine HG, Merz WG, Saral R. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 1987; 83:1103-10.
71. Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial Aspergillus infections: unique risk of bone marrow transplant recipients. Am J Med 1987; 83:709-18.
72. Rhame FS. Prevention of nosocomial aspergillosis. J Hosp Infect 1991; 18:466-72.
73. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
74. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-30.
75. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
76. Sobel JD. Practice guidelines for the treatment of fungal infections. Clin Infect Dis 2000; 30:652.
77. Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001; 33:139-44.
78. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.